Health Care [ 11/12 ] | Biotechnology [ 66/75 ]
NASDAQ | Common Stock
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.05 Increased by +66.67% | -0.06 Increased by +16.67% |
| May 9, 24 | -0.16 Increased by +11.11% | -0.07 Decreased by -128.57% |
| Feb 28, 24 | -0.11 Increased by +42.11% | -0.06 Decreased by -83.33% |
| Nov 8, 23 | -0.07 Increased by +41.67% | -0.08 Increased by +12.50% |
| Aug 8, 23 | -0.15 Increased by +28.57% | -0.12 Decreased by -25.00% |
| May 10, 23 | -0.18 Increased by +40.00% | -0.15 Decreased by -20.00% |
| Mar 1, 23 | -0.19 Increased by +34.48% | -0.13 Decreased by -46.15% |
| Nov 7, 22 | -0.12 Increased by +36.84% | -0.19 Increased by +36.84% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 126.67 M Increased by +34.04% | -15.70 M Increased by +63.69% | Decreased by -12.39% Increased by +72.91% |
| Mar 31, 24 | 110.40 M Increased by +27.97% | -48.42 M Increased by +8.53% | Decreased by -43.86% Increased by +28.52% |
| Dec 31, 23 | 115.08 M Increased by +30.63% | -33.84 M Increased by +39.42% | Decreased by -29.41% Increased by +53.63% |
| Sep 30, 23 | 103.50 M Increased by +26.70% | -21.58 M Increased by +35.18% | Decreased by -20.85% Increased by +48.84% |
| Jun 30, 23 | 94.50 M Increased by +17.06% | -43.23 M Increased by +30.45% | Decreased by -45.75% Increased by +40.58% |
| Mar 31, 23 | 86.27 M Increased by +9.60% | -52.93 M Increased by +37.92% | Decreased by -61.36% Increased by +43.35% |
| Dec 31, 22 | 88.10 M Increased by +7.23% | -55.87 M Increased by +32.92% | Decreased by -63.41% Increased by +37.44% |
| Sep 30, 22 | 81.69 M Increased by +2.70% | -33.29 M Increased by +33.82% | Decreased by -40.75% Increased by +35.56% |